Trending Stories on Eyewire+
LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD
The FDA?has granted?authorization to LumiThera allowing the company to market its Valeda?Light Delivery System. This approval, made under the De Novo authorization pathway, makes Valeda the first FDA-authorized device to... Read More
Alcon Unveils PRECISION7 One-Week Contact Lens with ACTIV-FLO Technology
Alcon?announced the US?launch of PRECISION7, the first contact lens designed for a 1-week replacement cycle. Leveraging the 7-day ACTIV-FLO?system, these lenses are designed to?deliver up to 16 hours of exceptional comfort and clear vision, even on the seventh day of wear. This product aims to bridge the gap between... Read More
Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2
Neurotech Pharmaceuticals?announced that the FDA?has extended the Prescription Drug User Fee Act (PDUFA) goal date by 3 months to allow time required for the FDA to review additional data provided by the company in response to recent requests from the FDA. Originally set for December 17, 2024,?the new PDUFA goal date for the biologics license application (BLA) of NT-501 (revakinagene taroretcel) as a treatment for macular telangiectasia type 2 (MacTel) is March 18, 2025. In June, the FDA granted?priority review for... Read More
EyewireTV | 11.06.2024
Leaders of several ophthalmic companies provide updates on their pipeline and new products on their special edition of EyewireTV.?Click here to check it out!
Latest In Podcasts
领英推荐
Case Review: Addressing Poor Medication Compliance With Interventional Glaucoma
Sila Bal, MD, MPH, invites I. Paul Singh, MD, to discuss a recent case in which a 72-year-old pseudophakic patient with open-angle glaucoma inquired about alternatives to topical treatments due to compliance issues. Click here to catch the latest episode.
AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD
The ELEVATUM study exclusively enrolled historically underrepresented patients in a study assessing faricimab (Vabysmo, Genentech/Roche) for DME. Were there any surprises in the data? Jeremiah Brown, MD, MS, sits down with New Retina Radio to review the philosophy behind the ELEVATUM study, discuss the study’s findings, and preview the next phases of the trial. Catch the latest episode here!
Eyewire News: The Podcast
We hear from executives representing pharma and device manufacturers in the anterior segment who provide updates on their companies’ recently launched products and those in development. Catch the latest episodes here!
Latest in Subspecialties:
Thank you for reading! We'll be back next week with another edition of?Eyewire+ Weekly Digest. For the most up to date news, please visit us at Eyewire+.